Datasets:
Javtor
/
biomedical-topic-categorization-validation

Dataset card Data Studio Files
xet
Community
PMID
int64
35.7M
36.4M
Title/Abstract
stringlengths
22
8.78k
MeshTerms
stringlengths
7
101
SemanticTypes
stringlengths
4
64
36,286,076
molecular detect haplorchi pumilio egg schoolchildren kome island lake victoria tanzania survey intestin helminth target schoolchildren primari school kome island lake victoria tanzania reveal small trematod egg children seem speci haplorchi heterophy egg molecular confirm haplorchi pumilio basi rdna sequenc
D006578;D014201
T047;T204
36,286,009
preval histoplasmosi among person advanc hiv diseas nigeria sought determin preval probabl dissemin histoplasmosi among advanc hiv diseas ahd patient nigeria conduct cross section studi site across geopolit zone nigeria identifi patient urinari sampl contain cd cell count clinic featur dissemin histoplasmosi test histoplasma antigen use histoplasma enzym immun assay particip recruit antigen posit histoplasma antigen posit particip signific lower p cd count also co infect tuberculosi antigen posit particip p previous receiv antiretrovir treatment histoplasmosi often hidden diseas among ahd patient nigeria histoplasma antigen test requir ahd packag care
D006660;D015658
T047
36,286,008
import haycocknema perplexum infect unit state report import case myositi caus rare parasit haycocknema perplexum australia year old man progress facial axial limb weak dysphagia dysphonia increas level creatin kinas hepat aminotransferas peripher eosinophilia year given extend high dose albendazol
D009348;D009220
T047;T204
36,285,986
differ sar cov clinic manifest diseas sever children adolesc infect variant sinc covid pandem began differ sar cov variant identifi associ higher transmiss ancestr nonvari strain januari januari assess differ clinic viral paramet conveni sampl covid outpati inpati year age columbus ohio usa accord infect variant identifi use mutat specif revers transcript pcr assay patient studi infect nonvari strain alpha variant delta omicron rate sar cov viral co infect compar across infect variant inpati acut delta omicron infect lower sar cov cycl threshold valu frequent fever respiratori symptom nonvari strain infect addit sar cov viral co infect presenc under condit independ associ wors clinic outcom irrespect infect variant
D060085;D000086382
T047;T067
36,285,985
mid infrar phototherm microscopi principl instrument applic midinfrar phototherm mip microscopi also call optic phototherm infrar ptir microscopi emerg tool bond select chemic imag live biolog materi sampl mip microscopi visibl probe beam detect phototherm base contrast induc vibrat absorpt submicron spatial resolut high spectral fidel reduc water absorpt background mip microscopi overcom limit infrar chemic imag method review summar basic principl mip microscopi differ origin mip contrast recent technolog develop push resolut speed sensit mip imag new stage emphas broad applic life scienc materi character provid perspect futur technic advanc
D008853
T059
36,285,981
character cytokin prolifer marker ki chronic rhinosinus recur nasal polyp chronic rhinosinus nasal polyp crswnp chronic inflamm mucosa nose paranas sinus presenc polyp affect popul cytokin analysi becom import research inflammatori mechan crswnp therefor aim investig complex appear relat distribut interlink il il il il il il il ki crswnp
D009298;D012220;D012852
T047
36,285,980
guidelin polish respiratori societi diagnosi treatment progress fibros interstiti lung diseas idiopath pulmonari fibrosi recommend develop answer previous formul question concern everyday diagnost therapeut challeng develop base review current literatur use grade methodolog expert suggest pf ild diagnos base combin differ criteria aggrav symptom progress radiolog lesion worsen lung function test paramet expert recommend precis diagnosi under diseas serolog test autoimmun diseas alway includ final diagnosi work multidisciplinari team mdt patient interstiti lung diseas ipf meet criteria progress fibrosi phenotyp monitor progress system autoimmun diseas regular monitor sign interstiti lung diseas manag patient interstiti lung diseas associ autoimmun diseas opinion mdt consid nintedanib rather pirfenidon introduc event ineffect therapi recommend treatment under diseas instanc possibl start antifibrot treatment without earlier immunomodulatori therapi also admiss use immunomodulatori antifibrot drug simultan recommend made termin anti fibrot therapi case note progress treatment pf ild ipf expert recommend principl non pharmacolog palliat treatment elig lung transplant appli patient interstiti lung diseas ipf progress fibrosi patient ipf
D054990;D017563
T047
36,285,979
icsultra laba treatment obstruct airway diseas consensus indian expert inhal corticosteroid ultra long act beta agonist icsulaba combin recent advanc armamentarium obstruct airway diseas oad combin icsulaba sever advantag creat favor landscap util fluticason furoatevilanterol trifenat ffvi one exampl icsulaba offer sever benefit drug conveni daili dose schedul high lipophil high receptor affin fluticason furoat along high function select quick onset action vilanterol howev global initi asthma gina well global initi chronic obstruct lung diseas gold guidelin clear defin posit icsulaba compar convent icslaba area uncertainti especi around appropri reliev strategi icsulaba asthma current consensus plan group indian pulmonolog expert provid clariti potenti use ffvi asthma copd clinic statement highlight consensus manuscript address crucial clinic question revolv around efficaci safeti ffvi compar convent icslaba identifi ideal patient profil use consensus paper also shed light upon appropri reliev use along ffvi asthma util ffvi base tripl therapi oad expert recommend mention paper serv guidanc pulmonologist well consult physician involv provid care oad patient help weigh various factor need taken account prescrib icsulaba combin
D001249;D029424
T047
36,285,978
nasal nitric oxid level improv diagnosi primari ciliari dyskinesia puerto rico primari ciliari dyskinesia pcd rare genet diseas character motil cilia dysfunct preval individu hispan popul puerto rico preval pcd unknown diagnosi pcd puerto rico challeng due lack diagnost technolog algorithm pcd diagnosi includ clinic histori genet test ciliari biopsi nasal nitric oxid nno level first time studi success implement measur nno level subject rspha cdel intron diagnost tool complement current algorithm pcd diagnosi island nno level differenti homozyg subject pcd due rspha cdel intron founder mutat compar healthi gender age match control subject vus negat genet test pcd acquisit state art diagnost tool nno posit impact expand current pcd diagnost capabl puerto rico founder genet mutat addit nno technolog promot earlier diseas screen recognit patient pcd island access nno help us proper character pcd diagnosi patient rspha cdel intron result find allow us part nation pcd foundat registri repres puerto rican hispan futur pcd multicentr clinic trial
D009569;D002925
T121;T197;T047
36,285,907
genom epidemiolog vibrio cholera zhejiang provinc china cholera caus vibrio cholera first report bangladesh india determin genom epidemiolog origin china sequenc isol collect zhejiang provinc china compar genom countri asia zhejiang isol fell cluster c c probabl origin india c thailand c c earli differ cluster harbor differ antimicrobi resist gene incac plasmid integr conjug element carri zhejiang isol new type differ icevchind sxt mo singl nucleotid polymorph presenc gene quinolon resist confer mutat sl parc si gyra occur zhejiang isol ctxb copi number differ among cluster find provid new insight prevent control cholera
D041242;D002771;D015363;D041241
T047;T007;T109
36,285,885
invas infect caus lancefield group cg streptococcus western australia australia epidemiolog data invas group cg streptococcus igcg infect spars intern link popul level hospit patholog death data use describ diseas burden western australia australia compar invas group streptococcus gas streptococcus pyogen infect case occur men patient igcg infect older median age year invas gas median age year p age sex adjust incid rate ratio year ci incid rate ratio indigen compar non indigen australian ci caus day death rate igcg infect compar invas gas p igcg infect common men older person higher death rate perhap reflect effect age comorbid incid death
D013297;D013290
T047;T007
36,285,883
fungal endophthalm outbreak cataract surgeri south korea novemb unusu increas fungal endophthalm case cataract surgeri report korea diseas control prevent agenc south korea initi outbreak investig identifi caus identifi case nationwid confirm probabl case patient expos surgeri ocular viscoelast devic ovd manufactur compani isol fusarium spp confirm case molecular identif fungal isol clinic sampl isol ovd confirm f oxysporum caus infect risk ratio fungal endophthalm compani ovd ci much higher risk manufactur product determin fungal endophthalm outbreak caus contamin lot ovd recommend discontinu use product earli recognit outbreak joint respons relat govern agenc reduc risk fungal endophthalm
D002387;D009877;D015821;D002386
T061;T047;T033;T190
36,285,882
incid etiolog healthcar util acut gastroenter communiti unit state knowledg epidemiolog sporad acut gastroenter age unit state limit septemb septemb survey kaiser permanent northwest member oregon washington usa collect data day preval dualli defin age diarrhea diseas relat health seek behavior subset particip obtain stool specimen use iter proport fit algorithm rake weight generat age preval annual rate estim detect norovirus rotavirus astrovirus sapovirus submit stool specimen real time quantit revers transcript pcr qrt pcr estim day preval age diarrhea annual rate casespersonyear age casespersonyear diarrhea age sought medic care almost one quarter stool specimen report age test posit viral pathogen compar without age
D005759;D012401;D017250
T047;T005
36,285,873
spatiotempor pattern anthrax vietnam anthrax prioriti zoonosi control vietnam geograph distribut anthrax remain defin challeng abil target area control analyz human anthrax case vietnam obtain anthrax incid nation provinci level nation trendlin case remain casesyear throughout year avail data indic control effort effect reduc diseas burden time anthrax case occur northern midland mountain region provinc lai chau dien bien lao cai ha giang cao bang son la experienc highest incid rate base spatial bay smooth map everi region vietnam experienc human anthrax case studi period clarifi distribut anthrax vietnam enabl us better identifi risk area improv surveil rapid clinic care livestock vaccin campaign
D000881;D001408
T047;T007
36,285,869
time antibiot therapi start de escal stop antibiot therapi propos stablish antimicrobi stewardship program current morbimort serious infect unaccept need promot increas efficaci empir target antibiotherapi could achiev initi come asp team aim promot increas efficaci antibiot therapi optim antibiot therapi sever critic point adequ time could achiev benefit surviv patient sever infect prompt initi empir treatment de escal perform appropri target treatment final curtail antibiot durat
D000073602
T058
36,285,868
treatment clostridioid difficil infect guidelin clinic practic clostridioid difficil infect cdi treatment guidelin publish howev incorpor recommend clinic practic rather irregular inconsist differ implement new guidelin due part varieti differ profession provid patient care well issu involv either access avail main requir implement includ appropri reflect patient stratif drug posit access drug well organ structur clinic pathway facilit function evalu manag cdi
D016360;D003015
T047;T007;T037
36,285,867
latent tuberculosi infect approach therapeut scheme tuberculosi continu major public health problem prioriti object implement earli diagnosi contact investig latent tuberculosi infect ltbi test world health organ conclud gold standard diagnosi ltbi tuberculin test igra interferon gamma releas assay indirect identifi tuberculosi infect test consid accept imperfect recommend regimen includ rifamycin equal effect less toxic adher long regimen isoniazid
D055985;D014376;D012294
T047;T195;T109
36,285,866
model bacteraemia risk predict clinic implic bacteraemia import consequ patient associ wors clinic outcom hand unnecessarili obtain sampl blood cultur increas cost workload microbiolog laboratori diagnosi impli time delay decis start antibiot treatment discharg admit patient must taken first attent therefor known blood cultur result manuscript review differ strategi base clinic score biomark use predict bacteraemia improv initi decis make
D016470
T047
36,285,865
new definit suscept categori eucast clinic applic januari european committe studi antimicrobi suscept eucast introduc chang definit clinic categori antibiot suscept object chang improv credibl categori optim lengthen surviv use avail antibiot face increas antimicrobi resist articl aim describ explain chang eucast criteria well make short review factor antibiot suscept criteria depend
D000900;D000890
T121;T195
36,285,864
rapid techniqu therapeut optim diagnost stewardship rapid microbiolog method provid clinician inform regard causat organ infect resist antimicrobi optim patient outcom antimicrobi use diagnost stewardship requir appropri test request inform translat appropri manag implement rapid techniqu also provid collabor opportun antimicrobi stewardship diagnost stewardship program contribut limit spread antimicrobi resist decreas mortal hospit length stay healthcar cost
D000073602;D000890
T121;T058
36,285,863
current manag cmv infect cancer patient solid tumor epidemiolog therapeut strategi littl evid avail regard incid cmv diseas patient solid cancer latest data show approxim patient cmv pcr posit develop clinic relev cmv viremia would requir specif therapi clinic arena cmv reactiv import differenti diagnosi infectolog work patient guidelin manag subject yet avail cmv reactiv consid differenti diagnosi patient sever declin lymphocyt count receiv chemoradiotherapi immunochemotherapi lymphocyt deplet block agent monitor cmv reactiv follow implement preemptiv strategi establish earli antivir treatment improv prognosi reduc morbid mortal patient
D003586;D009369
T047;T191
36,285,862
diagnost therapeut approach pulmonari infiltr cancer patient receiv immun checkpoint inhibitor advent immun checkpoint inhibitor ici target cytotox lymphocyt antigen ctla program cell death pd pd ligand pd l axi transform treatment paradigm multipl cancer type ici abl restor cell mediat antitumor respons entail increas risk infect per se howev immunotherapi associ uniqu form toxic due target effect healthi tissu excess enhanc immun respons form immun relat advers event ira although ici induc pneumon rank fifth ira term frequenc occurr associ relev attribut mortal review summar incid risk factor clinic radiolog present therapeut approach ici induc pneumon particular focus differenti diagnosi new worsen pulmonari infiltr cancer patient receiv ici therapi final impact risk opportunist infect ici immunosuppress therapi use treat associ ira review diagnosi manag suspect ici induc pneumon remain clinic challeng current manag cmv infect cancer patient solid tumor epidemiolog therapeut strategi
D000074322;D009369
T129;T121;T191;T116
36,285,861
norovirus infect model chronic recurr infect common variabl immunodefici common variabl immunodefici cvid frequent symptomat primari immunodefici pid general popul pid genet diseas share dysfunct immun system entail greater risk chronic recurr infect patient also develop chronic gastrointestin infect caus norovirus persist viral dissemin detect month primoinfect addit proport cvid patient show typic sever enteropathi present recurr diarrhoea intestin malabsorpt inflammatori lesion villous atrophi studi relat enteropathi chronic intestin infect caus norovirus
D017074;D017250;D005767;D006086
T047
36,285,860
covid donat transplant sar cov infect major impact donat transplant sinc cessat activ two year ago intern medic communiti rapid generat evid capabl sustain increas neccesari activ paper analys epidemiolog burden covid donat transplant pathogenesi infect relationship graft mediat transmiss impact vaccin donat transplant evolut donat spain throughout pandem lesson learn sar cov infect donor recipi posit pcr applic main therapeut tool recent approv treatment among transplant recipi
D000086382;D016377
T061;T047;T067
36,285,859
new treatment multidrug resist non ferment gram negat bacilli infect ceftolozanetazobactam ceftazidimeavibactam cefiderocol belong novel generat antibiot correspond lactam famili necessari new option treat infect caus gram negat non ferment multidrug resist bacilli due signific increas multidrug resist last decad know main characterist drug key correct use
D002442;D016905
T121;T047;T195;T109
36,285,858
treatment infect caus carbapenemas produc enterobacteral antibiot resist one main menac public individu health worldwid last two decad increas detect carbapenem resist enterobacteral report treatment infect caus strain therapeut challeng use carbapenem may benefici depend mic valu sourc infect new drug differ activ differ class carbapenemas develop show signific benefit
D001618;D001426
T123;T126;T116
36,285,857
controversi manag esbl produc enterabacteral clinic implic extend spectrum lactamas esbl produc organ current repres major health problem although recent publish guidelin still consid carbapenem treatment choic esbl produc infect necessari find non carbapenem lactam altern reduc effect associ overutil review focus altern carbepenem use possibl piperacillin tazobactam may altern clinic set low inoculum infect like urinari tract infect newer lactam lactamas inhibitor blblis potenti option current avail data support efficaci ceftazidim avibactam ceftolozan tazobactam suscept esbl produc enterobacteral esbl e wait result merino studi confirm whether ceftolozan tazobactam good option versus meropenem treat bloodstream infect caus esbl ampc produc enterobacteral
D065093;D000900
T121;T195;T109
36,285,856
antimicrobi resist one health antimicrobi resist one major health problem face st centuri nowaday understand global health without interdepend human anim environment dimens therefor logic adopt one health approach address problem review show collabor sector profess necessari order achiev optim health peopl anim plant environ
D000900;D000074823
T078;T121;T195
36,285,855
global strategi treatment hiv infect treatment hiv infect becom cornerston global control pandem due benefit individu health prevent transmiss hiv start peopl hiv infect quick possibl ideal start day diagnosi fail within first day antiretrovir regimen excel efficaci signific toxic conveni administr current avail initi antiretrovir treatment incorpor two three drug alway base second generat integras inhibitor
D015658;D019428;D019380
T121;T047
36,285,854
optim antimicrobi treatment sepsi sepsi repres serious risk life patient crucial start effect treatment extrem soon possibl chosen antibiot must activ pathogen produc condit addit must dose consid patient situat extrem consid necessari adjust dose edema drug reduc volum distribut hypoproteinemia drug bound protein high proport obes also requir use extern techniqu ecmo differ type hemodialysi hemofiltr
D018805;D006440
T061;T047;T046
36,285,853
current treatment nosocomi pneumonia ventil associ pneumonia hospit acquir pneumonia ventil associ pneumonia sever nosocomi infect lead high morbid mortal broad spectrum antibiot coverag like pathogen recommend intern guidelin inappropri empir treatment one import prognost factor knowledg local epidemiolog continu microbiolog surveil crucial improv clinic approach empir antimicrobi treatment develop protocol polici train healthcar profession prevent strategi pneumonia zero project improv implement antimicrobi stewardship practic aid earli de escal antibiot prevent resist
D053717;D003428;D011014
T047;T050
36,285,852
import aspect manag diabet foot infect diabet foot complex diseas one import complic infect risk limb loss sever case also life threaten condit sever guidelin avail order achiev implement standard care strategi howev consensus document address controversi issu aris diabet foot infect present articl aim review controversi aspect
D017719;D003141;D003920
T047
36,285,851
neutral antibodi sar cov infect covid pandem boost signific research develop monoclon antibodi mab treat prevent sar cov infect clinic trial shown mab safe effect prevent hospit death patient mild moder covid risk factor progress mab also effect treat sever diseas seroneg patient prevent covid far studi carri larg unvaccin popul time omicron variant describ futur research address limit provid inform specif popul group includ immunosuppress previous infect individu
D057134;D000086382
T129;T047;T116;T067
36,285,850
antivir drug sar cov use antivir drug repres import progress therapeut manag covid lead substanti reduct sar cov relat complic mortal immunocompet host peak viral replic occur around symptom onset prolong day window opportun give antivir accord earli rapid diagnost infect outpati clinic essenti well avail oral agent easili prescrib remdesivir demonstr efficaci hospit patient requir oxygen support mildmoder case avoid hospit howev intraven administr limit use among outpati molnupiravir nirmatrelvirritonavir potent oral antivir agent present review discuss potenti target sar cov overview main characterist clinic result avail antivir agent treatment sar cov
D000086402;D000086382
T005;T067;T047
36,285,849
manag hyperinflamm covid patient respons sar cov infect immun system physiolog upregul tri clear virus bodi failur compens inflammatori respons anti inflammatori respons lead dysregul immun system ultim lead situat uncontrol hyperinflamm call cytokin storm cytokin storm caus ard multi organ failur lead patient death review expos differ mechan inflammatori respons covid infect therapeut option treat process
D000086382
T047;T067
36,285,848
vulner sar cov infect diseas rip curl storm sar cov infect seem enter announc endem phase popul immun increas robust thank success vaccin booster campaign almost inevit exposur exposur virus truli serv natur immun mechan hand genet drift virus lead becom anoth catarrh agent endem human coronavirus howev lost sight still segment popul suscept sever covid candid continu receiv vaccin booster antivir drug initi stage infect
D000086382
T047;T067
36,285,838
enantioselect construct ortho substitut benzyl quaternari center use phenanthrolin pd catalyst method pd catalyz asymmetr conjug addit ortho substitut arylboron acid cyclic enon develop addit various ortho substitut arylboron acid substitut cyclic enon via catalysi chiral phenanthrolin pd complex form cyclic keton product bear ortho substitut benzyl carbon quaternari center good yield high enantioselect
D010618;D007659
T109
36,285,836
direct minisci type c h amid purin base method c h carboxyamid purin develop capabl direct instal primari secondari tertiari amid previous minisci type investig purin limit alkyl aryl herein present first method direct c h amid wide rang purin xanthin guanin adenin structur includ guanosin adenosin type nucleosid minisci type reaction also metal free cheap oper simpl scalabl applic late stage function biolog import molecul
D011687;D000225
T123;T114;T109
36,285,825
prospect evalu fatigu pediatr brain tumor patient treat radiat therapi background fatigu well establish consequ cranial radiotherapi survivor pediatr brain tumor less known acut fatigu radiotherapi treatment studi aim longitudin evalu fatigu newli diagnos pediatr patient brain tumor treatment method primari caregiv pediatr patient brain tumor complet proxi report parent fatigu scale assess prior radiotherapi week radiotherapi treatment associ clinic factor fatigu assess evalu multipl linear regress comparison fatigu radiat modal also analyz result total caregiv complet pre radiat fatigu assess report fatigu radiotherapi patient age year diagnosi diagnos medulloblastoma n primit neuroectoderm tumor n ependymoma n germ cell tumor n pineoblastoma n atyp teratoid rhabdoid n unspecif tumor n moder sever fatigu report major patient treatment craniospin irradi dose signific predictor fatigu p associ restrict first week therapi attenu therapi complet discuss although fatigu often consid long term consequ cranial radiotherapi pilot studi demonstr moder sever fatigu pervas prior radiotherapi persist throughout treatment pediatr patient brain tumor regardless radiat modal clinic factor addit research warrant establish link acut long term fatigu develop intervent mitig advers outcom
D001932;D018242;D002528
T191
36,285,820
mediat effect telomer length mitochondri dna copi number associ advers childhood experi ace central arteri stiff background advers childhood experi ace link increas cardiovascular diseas cvd risk previous report suggest acceler biolog age index telomer length tl mitochondri dna copi number mtdnacn may contribut associ ace cardiovascular health outcom examin potenti mediat effect tl mtdnacn associ ace central arteri stiff intermedi cardiovascular health outcom novel pathway link ace cvd risk among young adult method result one hundr eighti five n women mean age year individu provid inform ace tl kb per diploid cell mtdnacn copi per diploid cell quantifi use quantit polymeras chain reaction techniqu central arteri stiff measur carotid femor puls wave veloc cfpwv ms multipl linear regress analys use examin associ ace tl mtdnacn cfpwv ace posit associ cfpwv p tl p mtdnacn p invers associ cfpwv neither tl p mtdnacn p associ ace neither marker mediat associ ace cfpwv conclus increas number ace associ faster cfpwv thus greater degre central arteri stiff ace associ either tl mtdnacn suggest marker repres mediat pathway link ace central arteri stiff
D059289;D000076783;D002318
T033;T047;T046
36,285,818
recent advanc synthesi cyclic compound use dicyanoolefin versatil vinylog nucleophil dicyanoolefin util wide rang transform synthesi organ architectur review discuss mechan scope applic vinylog reaction dicyanoolefin synthesi cyclic molecul cover literatur last year
D009930
T109
36,285,798
hydrogen sulfid attenu lymphedema via induct lymphangiogenesi pikakt depend mechan background accumul evid suggest hydrogen sulfid h endogen produc gaseous molecul play critic role regul cardiovascular homeostasi howev littl known role lymphangiogenesi thus current studi aim investig involv h lymphat vessel growth lymphedema resolut use murin model assess under mechan method result murin model tail lymphedema creat wild type mice cystathionin lyas knockout mice evalu lymphedema day lymphat ablat cystathionin lyas knockout mice greater tail diamet wild type mice phenomenon associ inhibit repar lymphangiogenesi site lymphat ablat contrast administr h donor diallyl trisulfid amelior lymphedema induc format consider number lymphat vessel injur site tail vitro experi use human lymphat endotheli cell reveal diallyl trisulfid promot prolifer differenti tube like structur enhanc akt protein kinas b phosphoryl concentr depend manner blockad akt activ negat diallyl trisulfid induc prolymphangiogen respons lymphat endotheli cell furthermor effect diallyl trisulfid treatment lymphangiogenesi tail lymphedema model also negat inhibit phosphoinositid kinas pk akt signal conclus h promot repar lymphat vessel growth amelior secondari lymphedema least part activ akt pathway lymphat endotheli cell h donor could use therapeut refractori secondari lymphedema
D006862;D008209
T131;T197;T047;T046;T130
36,285,795
impact vitamin versus placebo cardiac structur function random clinic trial background vitamin supplement lead regress left ventricular lv hypertrophi improv lv function anim model howev limit data exist prospect human studi examin whether vitamin supplement improv cardiac structur function midlifeold individu larg random trial method result vital vitamin omega trial nationwid doubl blind placebo control random trial test effect vitamin iud n fatti acid gd cardiovascular cancer risk individu age year conduct substudi vital particip underw echocardiographi baselin year imag interpret blind investig central core laboratori primari end point chang lv mass among greater boston area particip attend clinic visit enrol studi seventi nine percent return follow analyz echocardiogram visit baselin median age year interquartil rang year men hypertens year chang lv mass signific differ vitamin placebo arm median g versus g respect p chang systol diastol lv function also differ signific arm signific chang cardiac structur function n fatti acid placebo arm conclus among adult age year neither vitamin n fatti acid supplement signific effect cardiac structur function year registr url https clinicaltrialsgov uniqu identifi nct vital nct vital echo
D002762;D015525
T121;T123;T127;T109
36,285,794
monitor nanoparticl dissolut via fluoresc colour shift la oh icg la oh ptc inorgan organ hybrid nanoparticl ioh nps indocyanin green icg perylen tetracarboxyl ptc fluoresc dye anion use emiss base monitor dissolut nanoparticl wherea icg show deep red emiss solid la oh icg ioh nps emiss ptc solid la oh ptc ioh nps complet quench due stack nanoparticl dissolut emiss freeli dissolv icg weak wherea freeli dissolv ptc show intens green emiss report synthesi ioh nps nanoparticl character well fluoresc properti avoid undesir energi transfer differ fluoresc dye emiss shift red intact solid nanoparticl green freeli dissolv dye anion indic nanoparticl dissolut shown aqueous system verifi vitro base first proof concept ioh np marker system interest monitor nanoparticl dissolut cell tissu small anim evalu cell process andor drug deliveri strategi
D053758
T073
36,285,790
earli midlif cardiovascular health influenc futur hdl metric women swan hdl studi background util high densiti lipoprotein cholesterol hdl c assess antiatherogen properti hdl may limit midlif women novel metric hdl function lipid content subclass may better reflect atheroprotect capac hdl support need evalu cardiovascular health affect metric women assess relationship earli midlif life simpl ls score health behavior compon futur hdl function hdl cholesterol efflux capac hdl phospholipid hdl triglycerid hdl particl hdl p size relationship ls score chang hdl metric time method result analyz women baselin age year white swan hdl studi women health across nation hdl studi baselin ls follow futur repeat hdl metric multivari linear mix model use higher ls score associ favor futur hdl profil higher hdl phospholipid total hdl p larg hdl p lower hdl triglycerid larger overal hdl size ideal bodi mass index associ higher hdl cholesterol efflux capac hdl phospholipid larg hdl p lower hdl triglycerid small hdl p larger overal hdl size ideal physic activ associ higher hdl phospholipid total larg medium hdl p ideal smoke associ less hdl triglycerid diet relat hdl metric higher ls score ideal bodi mass index associ slower progress hdl size time conclus novel hdl metric may better reflect clinic util hdl improv lifestyl midlif particular maintain ideal bodi mass index associ better futur hdl phenotyp
D001786;D002318
T047;T109
36,285,789
thirti year molecular dynam simul posttransl modif protein posttransl modif ptms integr compon cell respond perturb experiment advanc enabl improv ptm identif capabl throughput character structur chang caus ptms equat alter physiolog function maintain perspect cover histori comput model molecular dynam simul character structur implic ptms distinguish result differ molecular dynam studi base upon timescal simul analysi approach use ptm character last offer insight opportun modern research effort silico ptm character may proceed given current state art comput capabl methodolog advanc
D056004;D011499
T066;T044
36,285,788
burden stroke popul attribut fraction risk factor latin america caribbean background stroke burden character studi low middl incom countri scarc estim burden stroke risk factor latin america caribbean lac method result extract gbd global burden diseas studi data overal stroke subtyp ischem stroke intracerebr hemorrhag subarachnoid hemorrhag lac countri estim absolut age standard rate disabl adjust life year year life lost year live disabl death popul attribut fraction risk factor estim analys perform region nation level stroke subtyp sex age subgroup lac region fourth largest stroke burden worldwid million disabl adjust life year predomin attribut prematur death disabl adjust life year intracerebr hemorrhag primari caus overal stroke burden disabl adjust life year ischem stroke lead caus disabl total year live disabl haiti hondura highest age standard rate older adult men largest burden although women highest rate disabl socioeconom develop level influenc burden major risk factor cluster metabol high systol blood pressur popul attribut fraction high bodi mass index popul attribut fraction influenti hemorrhag event women older adult household air pollut import risk factor low incom countri lac conclus stroke burden stroke relat mortal lac higher worldwid averag howev stroke high prevent diseas region burden could reduc target modifi factor blood pressur bodi mass index research implement primari secondari prevent intervent need well integr nation stroke care program acut subacut rehabilit manag lac
D000071219;D020521
T081;T047
36,285,786
target temperatur manag postresuscit care incorpor result ttm trial cardiac arrest still account substanti proport cardiovascular relat death associ tremend risk neurolog injuri among survivor poor qualiti life critic determin surviv long term function status cardiac arrest time initi cardiopulmonari resuscit use extern defibril patient shockabl rhythm outcom still far satisfactori despit ongo effort improv cardiac arrest respons system well elabor postresuscit algorithm target temperatur manag wide rang c c one main therapeut strategi improv neurolog outcom postresuscit care recommend main base small random trial publish year ago recent data deriv ttm target hypothermia versus target normothermia hospit cardiac arrest trial includ patient challeng strategi show benefit target hypothermia c normothermia c c fever prevent temperatur manag lower temperatur also correl increas risk side effect without benefit ttm trial modif guidelin harmon temperatur manag normothermia might necessari
D007035;D007036;D058687;D016887
T033;T046;T037;T061
36,285,785
compar relationship genet proxi pcsk inhibit mood disord cognit dementia men women drug target mendelian random studi background pcsk proprotein convertas subtilisinkexin type inhibitor import therapeut option reduc cardiovascular diseas risk howev question remain regard potenti differ neuropsychiatr impact long term pcsk inhibit men women method result use pcsk gene singl nucleotid polymorph european ancestri base genom wide associ studi low densiti lipoprotein cholesterol n circul pcsk protein level n tissu specif pcsk gene express sex specif genom wide associ studi anxieti depress cognit insomnia dementia rang use drug target invers varianc weight mendelian random mr complementari mr method mr egger weight median weight mode investig potenti neuropsychiatr consequ genet proxi pcsk inhibit men women fail find evid surpass correct multipl comparison relationship genet proxi pcsk inhibit risk neuropsychiatr end point either men women drug target analys general well power detect effect estim sever hypothes threshold combin sex sex specif end point especi analys use pcsk instrument deriv protein express quantit trait loci mr estim across complementari mr method addit model use genet instrument deriv circul pcsk protein level tissu specif pcsk express align strengthen causal infer conclus genet proxi pcsk inhibit show neutral neuropsychiatr side effect profil major sex specif differ given statist power consider replic larger sampl well data ancestr popul necessari find may import clinic implic lipid lower drug prescrib practic side effect monitor approv futur pcsk therapi
D003072;D003704;D019964;D000071449
T126;T116;T048
36,285,784
tempor trend lipoprotein concentr atherosclerosi risk communiti studi background plasma lipoprotein lp concentr primarili determin genet factor believ remain stabl throughout life howev data scarc longitudin trend lp concentr time therefor unclear whether measur lp person life suffici cardiovascular risk assess adult method result lp concentr specif apolipoprotein concentr measur visit year apart adult particip aric atherosclerosi risk communiti studi mean age visit year respect particip categor baselin visit lp concentr normal mgdl borderlin high mgdl high mgdl compar adult lp chang mgdl visit lp chang mgdl multivari logist regress analysi use identifi covari associ chang lp time visit particip borderlin high lp concentr mgdl visit high lp concentr mgdl particip low lp mgdl high lp mgdl visit tend stay respect categori black race femal sex diabet hypertens total cholesterol albuminuria associ signific greater probabl lp chang mgdl time conclus result suggest adult borderlin high lp concentr may consid repeat monitor lp time particular black women diabet hypertens andor elev albuminuria
D050197;D003920;D006973
T047;T046
36,285,783
circul androgen concentr risk incid heart failur older men cardiovascular health studi background circul androgen concentr men declin age link diabet atherosclerot cardiovascular diseas ascvd similar relationship report low total testosteron incid heart failur hf remain unstudi free testosteron potent androgen dihydrotestosteron dht hypothes totalfre testosteron invers relat sex hormon bind globulin posit relat totalfre dht bear u shape relationship incid hf method result sampl men chs cardiovascular health studi without atherosclerot cardiovascular diseas hf serum testosteron dht concentr measur liquid chromatographi tandem mass spectrometri sex hormon bind globulin immunoassay free testosteron dht calcul total testosteron total dht sex hormon bind globulin albumin use cox regress estim relat risk hf adjust potenti confound men age year follow median year hf event adjust lower calcul free testosteron signific associ higher risk hf hazard ratio hr ci risk estim total testosteron hr ci total dht hr ci calcul free dihydrotestosteron hr ci sex hormon bind globulin hr ci direct similar statist signific conclus calcul free testosteron invers associ incid hf suggest contribut testosteron defici hf incid among older men addit research necessari determin whether testosteron replac therapi might effect strategi lower hf risk older men
D002318;D006333
T047;T046
36,285,782
length anticoagul provok venous thromboembol multicent studi real world practic mirror guidelin recommend background decad guidelin recommend limit month anticoagul treatment provok venous thromboembol vte close real world practic follow guidelin recommend well describ method result multicent retrospect cohort studi evalu trend anticoagul durat patient enrol maqi michigan anticoagul qualiti improv initi registri receiv anticoagul provok vte maqi registri compris center michigan manag patient long term anticoagul identifi patient warfarin patient direct oral anticoagul receiv anticoagul primari indic provok vte use predefin threshold day month plus buffer period predictor extend anticoagul use identifi use multivari logist regress patient receiv day anticoagul regardless medic use median th th percentil length treatment patient take warfarin day direct oral anticoagul day recurr vte odd ratio ci histori myocardi infarct ci direct oral anticoagul rather warfarin use ci independ associ prolong anticoagul conclus cohort patient provok vte patient receiv anticoagul longer guidelin recommend month demonstr potenti opportun improv care deliveri reduc anticoagul associ bleed risk
D054556
T047
36,285,768
size effect liposom centimet deep ultrasound switchabl fluoresc imag ultrasound control releas liposom wide use medic imag drug deliveri field due excel biocompat easi surfac modif recent lab report first time implement temperatur sensit indocyanin green icg encapsul liposom microparticl vivo ultrasound switchabl fluoresc usf imag previous studi show liposom microparticl achiev usf imag centimet deep tissu studi aim control size liposom nanoscal studi size effect usf imag depth also explor feasibl combin usf imag ultrasound control releas liposom synthes via hydrat method size control extrud process character paramet includ fluoresc profil spectra size stabil encapsul effici ultrasound control releas evalu usf imag blood serum conduct success phantom model imag depth studi conduct cm cm confirm nano size liposom stronger usf signal micron size liposom addit releas test indic ultrasound power exposur time affect releas effici increas power extend exposur time led higher releas effici studi show potenti use liposom usf imag ultrasound control releas
D008081;D061848
T060;T109
36,285,762
uniqu consider paediatr proxim phalanx fractur paediatr hand fractur care present uniqu consider challeng proxim phalanx injur locat review detail pearl examin injur paediatr hand immobilis consider treatment strategi treatment lead unnecessari stiff miss activ increas healthcar cost unnecessari surgic morbid undertreat promot malunion dysfunct fractur pattern discuss includ phalang head neck shaft base concept cover help optimis evalu treatment children injur proxim phalang level evid level v therapeut
D050723;D050278
T023;T037
36,285,761
analysi structur risk percutan pin distal radius fractur comparison two pin techniqu cadaver studi background stab incis blunt dissect prior wire placement believ decreas risk injuri under structur percutan pin distal radius fractur drf howev studi compar stab incis blunt dissect direct wire placement aim cadaver studi analys structur risk percutan pin drf compar two method wire placement method total cadav upper limb divid two group five five mm kirschner k wire insert distal radius fluoroscop control standard fashion simul percutan pin drf group k wire insert direct wherea group wire insert make stab incis blunt dissect reach bone cadaver limb dissect care measur distanc k wire branch superfici radial nerv srn cephal vein first dorsal compart determin structur injur pierc close contact k wire result k wire place wire close contact pierc under structur includ wire injur tendon six wire injur branch srn one wire injur cephal vein direct wire placement group result injuri eight structur stab incis blunt dissect prior wire placement group result injuri structur differ statist signific conclus percutan pin drf associ high risk injuri extensor tendon branch srn risk reduc make stab incis blunt dissect prior k wire placement
D011885;D005594
T061;T037
36,285,760
systemat review sensori outcom standard cross finger flap reconstruct fingertip defect background standard dorsal cross finger flap cff one common flap use fingertip reconstruct littl consensus regard sensori outcom associ flap systemat review evalu object sensori outcom paramet patient underw cff reconstruct method systemat review report use prisma protocol regist intern prospect regist systemat review literatur search done use term cross finger flap heterodigit finger tip transdigit data regard number patient follow durat sensori outcom includ point discrimin pd extract includ studi analysi perform use microsoft excel metaxl add softwar certainti assess summari find tabl creat use gradepro gdt result review includ studi patient found statist signific differ static pd recipi control finger pool weight mean differ wmd ci p n studi conclus dorsal cff reconstruct fingertip defect provid adequ sensori recoveri level evid level iii therapeut
D005383;D019651
T061;T037
36,285,759
sever life threaten sepsi complic infect thumb carpometacarp arthroplasti thumb carpometacarp cmc total joint arthroplasti common perform increas number worldwid present case prosthet joint infect pji lead sever septic shock dissemin septic emboli month follow unev thumb cmc arthroplasti extens life threaten infect follow thumb cmc arthroplasti report level evid level v therapeut
D052737;D018805
T047;T046;T030
36,285,758
intra medullari cannul headless compress screw bone graft fixat metacarp fractur high energi metacarp fractur present critic bone loss requir bone graft hardwar stabilis earli bone graft rigid intern fixat allow expedit patient recoveri plate fixat describ techniqu autolog bone graft use report present altern techniqu secur bone graft metacarp shaft intra medullari headless compress screw hcs present patient signific bone defect fourth fifth metacarp bridg use iliac crest cortico cancel bone graft fix hcs method fixat allow control earli activ mobilis bone graft incorpor excel activ rang motion demonstr level evid level v therapeut
D050279;D050723;D006230
T023;T037
36,285,757
mid term result first dorsal metacarp arteri flap thumb defect background thumb play import role function hand sensat reconstruct pulp import restor function thumb aim studi present outcom sensat island first dorsal metacarp arteri fdma flap use reconstruct skin defect thumb method patient fdma flap reconstruct thumb pulp defect orthopaed traumatolog clinic affili hospit includ studi includ eight thumb eight patient rang motion sensat cosmet satisfact donor recipi area evalu minimum year follow result partial complet flap failur mean static point discrimin mm mean semm weinstein monofila test score cortic orient observ patient near normal rang motion kapandji score regain patient conclus excel motion sensori outcom obtain follow fdma flap reconstruct thumb pulp defect donor morbid flap minim flap consid one primari option reconstruct thumb pulp defect level evid level v therapeut
D013933;D050279
T023
36,285,756
reliev pressur emerg depart new treatment pathway hand trauma patient three year experi patient background hand injuri signific rise burden emerg depart ed often lead protract wait time patient await specialist input combat new treatment pathway hand trauma introduc institut reduc wait time pressur ed method treatment pathway perform use wait time length stay cost metric measur prior follow introduct new treatment pathway result patient review total new pathway introduc number assess ed signific reduc year vs year p proport patient oper day assess signific increas vs patient p median wait time assess oper length stay also signific reduc follow introduct treatment pathway year hour year hour p conclus data year show chang maintain case continu improv sinc introduct new treatment pathway advoc use approach hand trauma centr worldwid replic improv patient care level evid level iii
D004636;D006230
T037;T073;T093
36,285,755
epidemiolog congenit hand differ tertiari hospit southern india establish new registri assess use swansonifssh oberg mansk tonkin classif background resourc challeng nation true magnitud congenit hand differ chd remain unknown due lack nation wide surveil system creat hospit base registri system aim determin preval distribut chd compar swansonifssh si oberg mansk tonkin omt classif method data children age year chd enter onlin registri classifi base si omt classif januari decemb preval distribut chd risk factor like famili histori summaris use descript analysi syndrom hered associ analys use fischer exact test odd ratio cluster column use compar two classif system result total patient chd present studi preval patient among unilater born consanguin marriag famili histori chd although statist signific bilater involv twice like hereditari compar unilater involv total differ syndrom identifi among patient holt oram syndrom common common chd radial longitudin defifici total children associ anomali could group syndrom two patient could classifi use either si omt classif conclus onlin registri establish effici way store analys data relat chd provid new inform preval south india similar exist literatur chd group si omt classif howev still remain condit unclassifi need nation registri cdh effect manag fund research level evid level iv epidemiolog
D038062;D000015
T019
36,285,754
biopsi distal radius implant calcium phosphat cement background calcium phosphat cap bone cement gradual replac new bone use gap filler detail model process still unclear uncertainti also present possibl releas cement particl resorpt phase caus local soft tissu reaction object studi perform comprehens histolog investig inject cap bone cement use void filler correct radius osteotomi adjac tissu reaction method fourteen patient median age year men women underw remov distal radius plate dorsal volar due tenosynov like symptom eleven studi patient went correct osteotomi cap bone cement three control patient previous surgeri three control consist correct osteotomi bone graft dorsal plate plate distal radius fractur dorsal volar plate biopsi taken bone cement bone junction bone bone graft bone junction bone juxtapos soft tissu interv correct cap cement surgeri biopsi median year result biopsi bone cement junction show differ stage new bone format cap immatur bone later matur well organis bone cement show sign osteoclast mediat resorpt cement particl macrophag multinucl giant cell mngc plasma cell observ soft tissu biopsi mngc internalis particl seen macrophag found along andor within tendon sheath patient group rare contain cement particl conclus gradual model cement well organis bone observ confirm osteoclast osteoblast coupl indic cement particl caus tenosynov like symptom
D017759;D011885;D013717
T047;T046;T037
36,285,753
atyp ulnar fractur older woman osteoporosi five year histori denosumab treatment case report atyp ulnar fractur auf rare condit may occur patient treat bisphosphon describ clinic cours patient auf treatment denosumab year old woman treat denosumab year experienc complet transvers fractur proxim left ulna fall stand height intraop photograph show cortic thicken around fractur site therefor diagnos patient auf perform intern fixat lock plate howev fractur occur month surgeri treat lock plate replac longer one bone graft one year second surgeri fractur heal knowledg second case report auf occur denosumab treatment case highlight import care follow patient receiv bisphosphon also denosumab level evid level v therapeut
D050071;D010024;D014458
T121;T047;T037
36,285,752
anthropometr studi proxim radius averag height thai women correl commerci avail radial head prosthes background radial head prosthes design western countri base anatom characterist western popul hypothesis prosthes larg averag height thai women object studi evalu anthropometr paramet proxim radius popul correl commerci avail prosthes method domin elbow thai women whose height cm studi use standard anteroposterior later radiograph imag head diamet thick distanc articular surfac radial tuberos narrowest intra medullari canal diamet narrowest outer diamet radial neck measur correl bodi height radiograph paramet assess use pearson correl coeffici pcc specif commerci metal radial head implant review use evalu relev radiograph paramet result mean minimum maximum head diamet mm mm respect thick mm distanc articular surfac tuberos mm intra medullari canal diamet mm outer diamet radial neck mm poor correl particip height paramet pcc particip smallest size prosthet design head diamet mm larger mm refer minor diamet minimum prosthet head thick greater averag valu particip design one particip outer neck diamet smaller smallest stem diamet three design conclus surgeon must awar commerci avail radial head replac implant may larg averag height thai women level evid level iv prognost
D011884;D058569
T023;T074
36,285,740
studi combin magic angl spin nmr small angl x ray scatter interact mixtur poli benzyl methacryl ionic liquid ethyl methylimidazolium bis trifluoromethanesulfonyl amid mixtur poli benzyl methacryl pbnma ethyl methylimidazolium bis trifluoromethanesulfonyl amid c mim ntf exhibit lower critic solut temperatur lcst type phase separ investig combin magic angl spin nmr spectroscopi small angl scatter perform gain new insight interact pbnma ionic liquid molecular mobil solut solvent interact system investig use h high resolut magic angl spin nmr appli magic angl spin frequenc khz allow identifi pbnma peak observ convent solut state nmr peak c mim almost coincid presenc absenc pbnma indic decoupl bulk solvent polym conform state pbnma c mim ntf investig use small angl x ray scatter sax pair distribut function pbnma chain calcul sax profil suggest pbnma adopt random coil conform upon dissolut c mim ntf combin studi clarifi decoupl low mobil polym random coil conform consid specif decoupl low mobil one origin decoupl conduct c mim ntf matrix polym addit increas temperatur induc downfield shift broaden c mim peak suggest larger amount c mim bound pbnma chain even temperatur approach lcst
D052578
T120;T103
36,285,714
develop spirocycl phosphoramidit base hybrid diphosphorus ligand enantioselect iridium catalyz hydrogen imin unsymmetr hybrid chiral diphosphorus ligand bear spirocycl phosphoramidit scaffold develop success appli iridium catalyz asymmetr hydrogen imin newli develop chiral iridium catalyt system wide rang imin includ steric hinder one could hydrogen give correspond optic activ amin high yield excel enantioselect ee util hydrogen demonstr prepar chiral fungicid benalaxyl
D007495;D007097
T196;T109
36,285,699
physiolog life histori chang associ season adapt cactophil drosophila mojavensi mani insect inhabit temper climat face chang environment condit throughout year depend speci environment fluctuat experienc within singl generat across multipl generat strategi deal season chang vari across popul drosophila mojavensi cactophil drosophila speci endem sonoran desert sonoran desert regular reach temperatur c summer month individu popul rare collect summer month simul cycl temperatur experienc mojavensi sonoran desert april juli four generat temperatur light control chamber understand physiolog life histori chang allow popul withstand condit contrast hypothesi summer aestiv found mojavensi continu reproduc summer month albeit lower viabil adult survivorship popul high reduc period expect stress resist increas summer month adult larval stage studi examin sever strategi withstand sonoran desert summer condit may inform studi desert endem speci
D004330;D000222
T040;T204
36,285,690
rapid prototyp function acoust devic use laser manufactur acoust pattern micro particl mani import biomed applic howev fabric microdevic cost labor intens among convent fabric method photo lithographi provid high resolut expens time consum ideal rapid prototyp test academ applic work demonstr high effici method rapid prototyp acoust pattern devic use laser manufactur method fabric newli design function acoust devic hour acoust devic fabric use method achiev sub wavelength complex non period pattern microparticl biolog object spatial resolut across larg activ manipul area mm
D000162;D007834
T074;T070;T073
36,285,665
divers pharmacogenom variant affect warfarin metabol sri lankan aim describ divers pharmacogenom variant affect warfarin metabol sri lankan materi method genotyp data filter anonym databas sri lankan minor allel frequenc maf calcul variant cypc vkorc cypf gene studi result overal cypc cypc allel maf ci ci respect cypc cypc allel maf ci ci respect maf vkorc variant rs rs rs rs ci ci ci ci respect maf cypf variant rs ci conclus compar popul frequenc studi variant signific differ sri lankan like account variabl warfarin dosag requir
D014859;D000071184
T045;T121;T131;T109
36,285,662
difficult marriag triarylcorrol zinc nickel ion coordin chemistri corrol wit great improv past year period tabl widen larg compar porphyrin howev ni zn ion common use porphyrin synthet theoret purpos spars report case corrol report synthet protocol prepar ni zn triarylcorrol complex case zn preliminari oxid free base corrol dmso neutral corrol radic necessari step obtain coordin metal ion direct reaction led format open chain tetrapyrrol ni complex could direct obtain heat free base corrol ni ii salt c dmso solut contain fecl non innoc natur corrol ligand complex elucid epr case zn deriv first spectroelectrochem character present
D015032;D011166
T123;T196;T121;T109
36,285,650
revolut pharmaco omic readi open new avenu materi precis medicin tweetabl abstract pharmaco omic revolut start wild stream sooner later expand dramat improv drug discoveri individu respons pharmacotherapi hope readi follow stream
D057285;D055432
T061;T091
36,285,648
control two compon modifi nanoparticl construct nanomateri nanoparticl self assembl technolog made great progress past year mani kind self assembl strategi modifi nanoparticl develop use construct nano aggreg design shape size type nanoparticl control compon modifi nanoparticl strategi wide use mani field medic diagnosi biolog detect drug deliveri materi synthesi sensor modifi compon dna chain polym chain protein even organ molecul base differ molecular conform chemic properti recent year self assembl two compon modifi nanoparticl gradual attract attent nanoparticl modifi two compon differ dna strand self assembl produc varieti nano arrang structur bcc fcc cubic crystal use crystal materi two compon modif hydrophil hydrophob polym produc vesicular aggreg use drug deliveri review summar latest experiment progress theoret simul self assembl two compon modifi nanoparticl includ differ dna chain differ polym chain dna polym chain protein polym chain differ organ molecul self assembl characterist applic prospect discuss compar singl compon modifi nanoparticl two compon nanoparticl differ tether molecul molecular chain multifunct regul differ modifi compon type nanoparticl ultim expand scope applic
D053758;D049329
T073
36,285,636
set delet attenu isoproterenol induc cardiac fibrosi delay cardiac dysfunct cardiovascular diseas main caus death worldwid recent studi reveal influenc histon modifi enzym cardiac remodel heart dysfunct set methyltransferas regul express sever gene methyl histon modul activ non histon protein howev role set cardiac remodel heart dysfunct remain unknown address question wild type wt set knockout ko male mice inject isoproterenol salin wt mice inject isoproterenol display decreas set activ heart addit wt set ko mice inject isoproterenol exhibit cardiac hypertrophi interest set delet exacerb cardiac hypertrophi respons isoproterenol attenu myocardi fibrosi echocardiogram reveal wt mice inject isoproterenol lower eject fraction fraction shorten increas e wave deceler time ea ratio compar control convers set ko mice show alter paramet respons isoproterenol howev prolong exposur isoproterenol induc cardiac dysfunct wt set ko mice isoproterenol set delet chang transcript profil heart moreov set delet increas express pgc mitochondri dna content heart reduc express cellular senesc inflamm marker respons isoproterenol taken togeth data suggest set delet attenu isoproterenol induc myocardi fibrosi delay heart dysfunct suggest set play import role cardiac remodel dysfunct respons stress
D020257;D009202
T047;T042
36,285,626
finnish genet heritag diagnosi translat research isol popul valuabl discoveri rare monogen diseas causat genet variant finnish diseas heritag fdh exampl group hereditari monogen disord caus singl major usual autosom recess variant enrich popul due sever past genet drift event interest distinct subpopul remain finland maintain uniqu genet repertoir thus fdh diseas persist facilit vigor research under molecular mechan develop treatment option review summar current status fdh includ recent discov fdh disord introduc set recent identifi diseas share common featur tradit fdh diseas review also discuss new era popul base studi combin various form big data identifi novel genotyp phenotyp associ behind complex condit exemplifi finngen project addit pathogen variant unequivoc causat role diseas phenotyp sever risk allel correl certain phenotyp featur identifi among finn emphas broad valu studi genet isol popul
D057170
T062
36,285,621
kyrgyzstan health system review analysi kyrgyz health system review develop organ govern financ provis servic health reform health system perform mandatori health insur place mandatori health insur fund mhif ministri health act singl public payer almost hospit provid primari care benefit packag public cover servic defin state guarante benefit programm sgbp howev mani servic requir co payment popul cover mandatori health insur health expenditur per capita one lowest european region due countri small gdp per capita privat spend almost entir form pocket expenditur includ inform payment account health expenditur financi protect undermin low level public spend health result financi hardship peopl use health servic well develop network health facil geograph distribut health worker uneven overal shortag famili doctor access health servic remain challeng exacerb covid pandem improv made recent year communic noncommunic diseas still pose major problem life expect prior covid pandem one lowest european region
D000086382
T047;T067
36,285,619
effect feasibl accept hiv servic deliveri privat pharmaci sub saharan africa scope review privat pharmaci understudi set differenti deliveri hiv servic may address barrier clinic deliv servic stigma long wait time understand potenti pharmaci deliv hiv servic sub saharan africa conduct scope review publish grey literatur
D015658;D010594;D065129
T061;T073;T093;T047;T058
36,285,618
measur patient engag hiv care sub saharan africa scope studi engag hiv care multi dimension dynam process critic maintain success treatment outcom howev measur engag standard comprehens undermin understand scope challeng engag whether intervent impact complic patient programm level decis make studi identifi character measur engag support consist comprehens evalu
D010358;D015658
T081;T047;T058;T080
36,285,612
design synthesi visibl light respons azobenzen build block chemic biolog tetra ortho fluoro azobenzen class photoswitch use construct visibl light control molecular system use achiev spatio tempor control properti chosen bioactiv molecul howev introduct differ substitu tetra fluoro azobenzen core signific affect photochem properti switch compromis biocompat herein explor effect use substitu function point attach handl water solubil group photochem properti photochrom system general test fluorin azobenzen exhibit favor photochem properti high photostationari state distribut long half live organ solvent water one azobenzen build block function trehalos group enabl uptak photoswitch mycobacteria follow metabol uptak incorpor trehalos base azobenzen mycobacteri cell wall demonstr photoswitch azobenzen isol total lipid extract
D055668;D014199
T121;T123;T070;T109
36,285,606
skelet muscl kidney crosstalk chronic kidney diseas function complex organ requir constant delic balanc process within cell tissu organ system grow appreci role signal crosstalk connect differ organ system bodi even tissu tradit classifi inert term capac produc chemic signal act organ system mani secret molecul shown contribut exacerb varieti function diseas organ system even two organ function link exampl strong associ skelet muscl atrophi dysfunct patient chronic kidney diseas ckd identif molecul produc secret skelet muscl exist time emerg evid skelet muscl may direct affect kidney function convers factor produc secret kidney various model ckd shown contribut reduc muscl function review focus crosstalk direct skelet muscl kidney emphasi direct interact organ use exampl secret factor produc muscl kidney includ activin myostatin microrna irisin mitsugumin often pathophysiolog condit understand kidney skelet muscl interact key elucid pathophysiolog process drive health diseas
D051436;D035683
T123;T047;T114
36,285,602
impact covid pandem tb servic art programm low middl incom countri multi cohort survey covid stretch healthcar system limit particular set pre exist high burden infecti diseas includ hiv tuberculosi tb studi impact covid tb servic antiretrovir therapi art clinic low middl incom countri
D015658;D000086382;D014376;D004202
T131;T047;T167;T067
36,285,601
synthet access oxoketen amin nucleophil addit enol silan deriv palladium ii enol carbodiimid synthet import oxoketen amin intermedi access readili avail inexpens carbodiimid start materi via nucleophil addit palladium enol deriv enol silan precursor oper simpl method featur mild reaction condit includ open air atmospher ligand free metal catalysi broad substrat scope multi gram scalabl select synthet applic take advantag enamin charact oxoketen amin involv c nucleophil addit electrophil system includ unsatur ester azo dicarboxyl aralkyl halid aldehyd demonstr
D010165;D012821
T104;T196
36,285,593
liver resect versus microwav ablat hepatocellular carcinoma ideal candid ablat per barcelona clinic liver cancer stage propens score match invers probabl treatment weight analysi liver resect lre microwav ablat mwa hepatocellular carcinoma hcc wide compar
D006528;D008113;D017115
T061;T191
36,285,587
enhanc dnazymat activ use iter silico matur dnazym base catalyt nucleic acid biosens technolog recognis valuabl biosens tool diagnost medicin seen cheaper stabl altern antibodi enzym howev like enzym discoveri method exist predict dnazym sequenc result high catalyt activ use comput softwar silico work iter silico matur vitro evalu appli dnazym oligodeoxynucleotid odn sequenc elucid novel synthet sequenc enhanc dnazym activ alreadi well known model dnazym g quadruplexhemin complex iter eight generat elucid synthet sequenc five time faster origin parent sequenc combin molecular dynam simul found pod mimick activ larg affect dock mode tight lock complex ultim theoret model show signific sequenc depend
D021881;D054856
T126;T116;T114;T086
36,285,578
systemat review electron health record manag chronic condit among displac popul object studi assess impact electron health record ehr health outcom care displac peopl chronic health condit determin barrier facilit ehr implement displac popul
D057286;D012036
T098;T170;T073
36,285,569
infant born follow sar cov infect pregnanc evalu outcom neonat born mother sever acut respiratori syndrom coronavirus sar cov infect pregnanc dynam placent transfer matern antibodi persist infanc
D000086382;D011251
T047;T067
36,285,567
characterist outcom children discharg nasoenter feed tube describ characterist outcom children discharg hospit new nasoenter tube net use acut hospit
D010351;D011014
T058;T050;T047
36,285,562
overexpress microrna inhibit apoptosi autophagi cell model parkinson diseas downregul ras relat c botulinum toxin substrat rac manuscript retract due non origin duplic content figur imag rais concern regard credibl studi refer wusheng lu jinhuang lin dequan zheng chunyong hong laishun ke xinyu wu peineng chen overexpress microrna inhibit apoptosi autophagi cell model parkinson diseas downregul ras relat c botulinum toxin substrat rac med sci monit e doi msm
D035683;D010300
T123;T047;T114
36,285,538
revisit signific keratin express complex epithelia larg group keratin gene n human genom code intermedi filament form protein show differenti regul epitheli cell tissu keratin express high inform type epitheli tissu differenti status constitu cell biolog context eg normal versus diseas set foundat principl under use keratin express gain insight epitheli cell tissu primarili origin pioneer studi conduct recent emerg singl cell transcriptom provid opportun revisit principl gain new insight epitheli biolog analysi singl cell rnaseq data collect human mous skin confirm long held view regard quantit import pairwis regul specif keratin gene keratinocyt surfac epithelia furthermor analys confirm extend notion chang keratin gene express occur gradual progenitor keratinocyt commit undergo differenti challeng prevail assumpt specif keratin combin reflect mitot versus post mitot differenti state find provid blueprint similar analys tissu warrant nuanc approach use keratin gene biomark epithelia
D007633;D015603
T123;T116;T025
36,285,522
save live ask question nurs experi suicid risk assess telephon counsel primari health care explor nurs experi suicid risk assess telephon counsel tc primari health care phc
D013405;D009726
T033;T097
36,285,507
high resolut atlas spectrum tubercul covid lung lesion current understand spectrum tb covid lesion human lung limit relianc low resolut imag platform provid accur represent lesion type within context whole lung character tb covid lesion appli micronanocomput tomographi surgic resect postmortem paraffin embed human lung tissu defin spectrum tb patholog includ cavitari lesion calcium deposit outsid insid necrot granuloma mycetoma vascular rearrang identifi unusu spatial arrang vasculatur within entir covid lobe segment blood vessel reveal microangiopathi associ hemorrhag notabl segment patholog anomali reveal hidden patholog structur might otherwis disregard demonstr power method visual patholog tb lung tissu whole covid lobe find provid unexpect new insight spatial organ spectrum tb covid lesion within framework entir lung
D000086382;D014376;D009169
T047;T007;T067
36,285,501
evolut marsupi social organ general believ marsupi primit placent mammal main solitari live repres ancestr form social organ mammal howev field studi observ pair group live marsupi speci compar studi social evolut ever done describ result primari literatur research marsupi social organ indic speci live pair group mani show intra specif variat social organ use bayesian phylogenet mix effect model weak phylogenet signal found solitari live like ancestr form posterior probabl high uncertainti combin probabl part sociabl marsupi ancestor overlook australian marsupi group live speci less like found tropic rainforest speci variabl social organ associ low unpredict precipit repres desert result suggest modern marsupi sociabl previous believ strong support ancestr state strict solitari live assumpt solitari ancestr state mammal may also need reconsider
D008394
T015
36,285,500
hybrid order drive factor behind bias duplic gene loss among hexaploid solanacea model post hexaploidi evolut four genom solanacea group flower plant compris tomato potato relat hexaploidi genom descend occur two sequenti allopolyploidi event mark unequ loss duplic gene differ progenitor subgenom contrast hexaploid brassicea broccoli relat subgenom surviv gene arriv last hexaploidi among solanacea preserv subgenom descend one origin two tetraploid progenitor fact last arriv subgenom plant actual fewest surviv gene modern genom explor whether distribut repetit element res genom explain bias gene loss signal find broad consist role high densiti drive gene loss res turn quick littl signal condit time paleopolyploidi extant modern genom
D019657;D019607
T002
36,285,499
silkworm gustatori receptor bmgr dedic detect isoquercetin mulberri gustatori system phytophag insect use perceiv feed stimul deterr involv insect decis feed particular plant process gustatori receptor grs recogn divers phytochem provid molecular basi tast percept silkworm repres lepidoptera speci develop strong feed prefer mulberri leav mulberri deriv flavonoid glycosid isoquercetin requir induc feed behaviour howev correspond grs isoquercetin under molecular mechan remain unclear studi use molecular method voltag clamp record feed assay identifi silkworm bmgr tune isoquercetin use qrt pcr confirm bmgr high express mouthpart fourth fifth instar larva function analysi show oocyt express bmgr bitter clade respond mulberri extract among test chemic bmgr specif recogn isoquercetin prefer isoquercetin observ bmgr knock group tune bmgr isoquercetin demonstr meaning explain silkworm mulberri feed mechan molecular level thus provid evid feed relationship studi phytophag insect host plant
D012831;D031625;D029721
T123;T002;T116;T204
36,285,498
human trade whole bodi energi cost avoid overburden muscl walk metabol cost minim thought underscor neural control locomot yet avoid high muscl activ caus fatigu often outperform energi minim comput predict human gait discern relat import criteria human walk prove elus part empir decoupl explicit decoupl whole bodi metabol cost fatigu like muscl activ cost estim electromyographi pit one anoth use two distinct gait task experienc compet cost particip n chose task avoid overburden muscl fatigu avoid expens higher metabol power p muscl volum normal activ close model energi use also minim particip decis p demonstr muscl activ best inaccur signal metabol energi energi minim observ advers effect muscl activ cost decoupl whole bodi metabol muscl activ cost provid among first empir evid human embrac non energet optim favour clear defin neuromuscular object find indic local muscl fatigu effort may well key factor dictat human walk behaviour evolut
D004734;D016138
T039;T040;T169;T056
36,285,497
tree ring evid ecolog stress memori plant experienc stress could develop abil reshap respons toward present stress base past stress experi call ecolog stress memori esm import plant acclim repeat stress although esm larg report remain unclear whether esm could improv tree resist recurr stress subsequ decad explor tree ring network tree long live junip forest tibetan plateau compar perform tree radial growth past sequenti growth stress found tree could obtain esm anteced stress elev resist subsequ stress sever year even decad posit effect esm associ post stress recoveri tree slow recoveri trajectori anteced stress show signific improv resist subsequ stress tree extrem fast post stress recoveri show decreas resist subsequ stress result impli temporari depress tree radial growth anteced stress might trigger long storag esm incorpor posit effect esm relationship esm activ post stress recoveri futur earth system model could advanc capac predict forest dynam forest ecosystem stabil futur stress condit
D014197;D018653
T002
36,285,496
selfish herder finish last mobil anim group predat power select pressur probabl driver mani anim speci live group one key explan evolut social selfish herd model describ individu stay close other effect put neighbour predat surviv incom attack model often illustr refer herd ungul school fish flock bird yet natur predat strike herd often found flee cohes direct jostl posit centr group paper highlight critic assumpt origin model name prey move respons posit predat model relax assumpt find individu adopt selfish herd behaviour often like captur end back flee herd contrast individu adopt rule neighbour neighbour align abl avoid rearmost posit move herd align success selfish herd across much paramet space may explain high align flee behaviour common observ natur
D011235;D012919
T054
36,285,495
disentangl development origin novel phenotyp enhanc versus revers environment induc gene express increas evid suggest mani novel trait might origin via plastic led evolut ple yet littl known development process underpin ple especi earli stage one process phenotyp accommod occur respons chang environ organ experi adjust across variabl part phenotyp improv fit ask environment induc chang gene express enhanc revers phenotyp accommod novel complex phenotyp spadefoot toad tadpol spea multiplicata gene expect affect environ phenotyp accommod liver brain howev although phenotyp accommod primarili revers environment induc chang gene express liver tissu enhanc chang brain tissu thus depend tissu phenotyp accommod may either minim function disrupt via revers gene express pattern promot novelti via enhanc exist express pattern studi therebi provid insight development origin novel phenotyp incipi stage ple
D005075;D001001
T045;T011
36,285,494
domin carnivor loss benefit nativ avian invas mammalian scaveng scaveng larg carnivor integr ecosystem function limit build carrion facilit widespread energi flow howev top carnivor declin across world trigger trophic shift within ecosystem compar find previous work predat declin area recent nativ mammalian carnivor loss specif investig top control util experiment place carcass two mesoscaveng invas feral cat nativ forest raven raven profit carnivor loss scaveng five time longer absenc nativ mammalian carnivor cat scaveng half carcass region without domin nativ carnivor eight time area carnivor high densiti carcass persist longer three week monitor period absenc nativ mammalian carnivor area high carnivor abund carcass fulli consum result reveal top carnivor loss amplifi impact associ carnivor declin increas carcass persist carrion access smaller scaveng suggest even low densiti nativ mammalian carnivor fulfil ecolog function demonstr signific global carnivor conserv support manag approach trophic rewild
D017753;D002335
T070;T008;T082
36,285,493
local adapt host parasitoid shape hamiltonella defensa genotyp across aphid speci facult symbiont common insect provid host signific adapt yet still limit understand shape distribut particular symbiont strain common host speci yet absent other address question genotyp defens symbiont hamiltonella defensa aphid speci common carri microb found hamiltonella strain strong associ specif aphid speci strain found one host speci rare occur other explain associ reciproc transfer hamiltonella strain three aphid speci acyrthosiphon pisum macrosiphoniella artemisia macrosiphum euphorbia assess impact hamiltonella strain stabil symbiosi aphid fecund parasitoid resist demonstr hamiltonella strain found natur local adapt specif aphid host ecolog aphid tend carri hamiltonella strain effici transmit offspr non lethal provid strong protect domin parasitoid speci result suggest facult symbiont distribut shape select natur enemi host result local adapt symbios provid signific benefit prevail natur enemi
D001042;D014863
T204
36,285,490
elucid effect environment exposur use human induc pluripot stem cell diseas model induc pluripot stem cell ipsc power model system medic discoveri translat research date studi focus potenti ipsc regen medicin drug discoveri diseas model howev ipsc also power model system investig effect environment exposur cardiovascular system emerg e cigarett air pollut marijuana use opioid microplast novel cardiovascular risk factor ipsc potenti elucid effect toxin bodi use convent two dimension array advanc tissu engin approach organoid three dimension model effect environment factor may enhanc genet polymorph make individu suscept effect toxin ipsc diseas model may reveal import gene environ interact exacerb cardiovascular diseas predispos individu advers outcom thus ipsc gene edit techniqu could play pivot role elucid mechan gene environ interact understand individu variabl suscept environment effect
D057026;D066300
T025;T073